Welcome to the REVEAL Study website
The REVEAL study is an international clinical trial that aims to find out if treating cholesterol
with a new drug called anacetrapib will drive down the risk of heart attacks, deaths from heart
disease and other vascular diseases.
What does the REVEAL study involve?
REVEAL will involve over 30,000 men and women who already have some form of circulatory disease.
Participants will be recruited from the UK, North America, China, Germany, Italy and Scandinavia.
All study participants will be given atorvastatin (a commonly used "statin" drug) to ensure good
control of LDL ("bad") cholesterol.
Participants will also receive either anacetrapib or matching placebo (dummy) tablets daily
The study will continue for at least four years.
The primary aim of the study is to see whether fewer participants given anacetrapib have heart
attacks, revascularization procedures or die from coronary heart disease than do those given
the placebo tablets.
Who is responsible for the REVEAL study?
The study is being coordinated by the Clinical Trial Service Unit (CTSU)
at Oxford University.
Click here for the REVEAL press release of 02 September 2013
In the meantime, if you would like further information, please contact us on 0800 585323 or email